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Inhibition of Rho at different stages of thymocyte development
gives different perspectives on Rho function
Steve Cleverley*, Stefan Henning† and Doreen Cantrell*
Development of thymocytes can be staged according to
the levels of expression of the cell-surface markers
CD4, CD8, CD44, CD25 and CD2. Thymocyte
development is regulated by a complex signalling
network [1], one component of which is the GTPase
Rho. The bacterial enzyme C3 transferase from
Clostridium botulinum selectively ADP-ribosylates Rho
in its effector-binding domain and thereby abolishes its
biological function [2,3]. To explore the function of Rho
in thymocyte development, we previously used the
proximal promoter of the gene encoding the Src-family
kinase p56lck to make transgenic mice that selectively
express C3 transferase in the thymus [4–6]. In these
mice, which lack Rho function from the earliest
thymocyte stages, thymocyte numbers are reduced by
approximately 50- to 100-fold. Here, we describe
transgenic mice that express C3 transferase under the
control of the locus control region (LCR) of the CD2
gene; this regulatory element drives expression at a
later stage of thymocyte development than the lck
proximal promoter [7]. In these mice, thymocyte
numbers were also reduced by 50- to 100-fold, but
unlike the lck–C3 mice, in which the reduction
predominantly results from defects in cell survival of
CD25+ thymocyte progenitors, the CD2–C3 transgenic
mice had a pre-T-cell differentiation block at the CD25+
stage after rearrangement of the T-cell receptor (TCR) β
chains. Analysis of CD2–C3 mice demonstrated that
Rho acts as an intracellular switch for TCRβ selection,
the critical thymic-differentiation checkpoint. These
results show that Rho-mediated survival signals for
CD25+ pre-T cells are generated by the extracellular
signals that act on earlier thymocyte precursors and
also that temporal cell-type-specific elimination of Rho
can reveal different functions of this GTPase in vivo.
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Results and discussion
We generated transgenic mice that expressed C3 trans-
ferase under the control of the human CD2 promoter (see
Figure 1 for stages of thymocyte development and kinetics
of CD2–C3 and lck–C3 expression). Thymi from three
independent lines of CD2–C3 transgenic mice were consis-
tently smaller than those of littermate controls (Figure 2a).
Thymocyte numbers from 4-week-old CD2–C3 mice were
reduced approximately 50- to 100-fold over those of normal
littermate controls (Figure 2b). Thymi from CD2–C3 mice
almost exclusively contained CD4–CD8– double-negative
(DN) cells (Figure 2c). Calculations of absolute cell
numbers showed that the levels of CD4–CD8– DN cells in
CD2–C3 mice were within the normal range, but all further
stages of thymocyte development were effectively absent.
Loss of Rho function in CD2–C3 transgenic mice therefore
blocked thymocyte differentiation at the CD4–CD8– DN
stage. CD4–CD8– DN thymocytes from CD2–C3 mice con-
tained a marked increase in the CD44–CD25+ subpopula-
tion compared with non-transgenic littermate controls
(Figure 2d). CD25 levels on CD44–CD25+ cells from
CD2–C3 mice were elevated compared with CD25 levels
on control cells (Figure 2e). CD25 is normally downregu-
lated upon expression of a pre-TCR complex on the thy-
mocyte surface membrane. Failure of the pre-TCR
complex either to be expressed or to signal correctly results
in increased levels of CD25 expression [8–10]. Increased
levels of CD25 are therefore consistent with a block in pre-
TCR expression or function.
Differentiation of CD44–CD25+ thymocytes depends on
cells successfully rearranging their TCRβ loci and express-
ing a functional pre-TCR on their surface; failure of
β-chain rearrangement results in a differentiation block.
We investigated whether rearranged β chains were present
in CD25+ cells from CD2–C3 mice by intracellular staining
with an antibody to a common β-chain epitope [11].
β-chain rearrangement is accompanied by a transition from
small ‘E’ cells (β-chain-negative) to large blast-like ‘L’
cells (all of which express rearranged β subunits) [12].
CD25+ E and L cells were present in CD2–C3 mice.
CD25+ L cells from CD2–C3 mice all expressed readily
detectable levels of intracellular TCRβ subunits, although
at slightly lower than normal levels (Figure 2f).
The differentiation block in thymocytes that fail to
express a pre-TCR complex can be overcome by expres-
sion of transgenes encoding mature, rearranged TCRαβ
chains [13]. To determine whether TCR expression could
induce the differentiation of thymocyte progenitors into
CD4+CD8+ (double-positive; DP) cells in CD2–C3 mice,
these mice were crossed with transgenic mice expressing
the HY-TCR, which recognises a male antigen-derived
peptide in the context of a major histocompatibility
(MHC) class I molecule. Male HY-TCR mice show
massive deletion of CD4+CD8+ thymocytes [14], whereas
in female HY-TCR mice, positive selection of CD8+ single-
positive (SP) thymocytes from CD4+CD8+ DP thymocytes
proceeds normally. Surface expression levels of HY-TCR
were similar on CD4–CD8– DN thymocytes isolated from
HY-TCR mice and CD2–C3/HY-TCR double-transgenic
mice (Figure 2g). Female CD2–C3/HY-TCR mice con-
tained no CD4+CD8+ DP cells (Figure 2h). Thus, expres-
sion of a stable, mature TCR complex in CD2–C3 mice
could not induce the differentiation of pre-T cells from the
CD4–CD8– DN stage to the CD4+CD8+ DP stage. These
results do not preclude the possibility that Rho might reg-
ulate the surface expression and/or stability of a pre-TCR
complex, but they do show that when there is stable TCR
expression, TCR signalling requires endogenous Rho
function to drive thymocyte differentiation at the pre-T-
cell stage. Rho function is therefore required for signalling
by the pre-TCR complex, thereby acting as an intracellu-
lar switch for the critical checkpoint of TCRβ selection. 
Thymi from lck–C3 transgenic mice were small and
hypocellular and had external morphology indistinguishable
from that of CD2–C3 thymi (Figure 2a). However, lck–C3
thymi showed a completely different pattern of thymocyte
differentiation from that of CD2–C3 thymi (Figure 3a):
lck–C3 thymi contained CD4–CD8– DN, CD4+CD8+ DP
and CD4+ or CD8+ SP cells, whereas CD2–C3 thymi lacked
DP and SP cells. Moreover, CD4–CD8– DN cells from
lck–C3 thymi were not CD25+ and were mostly
CD44+CD25– (Figure 3b). In CD2–C3 mice, CD44–CD25+
cells represented the predominant subpopulation of
CD4–CD8– DN cells. The depletion of CD25+ thymocytes
in lck–C3 transgenic mice is explained by massive apoptosis
[4,5], detectable by staining with the fluorescent dye
7-amino-actinomycin D (7AAD), which detects apoptotic
cells on the basis of increased cell membrane permeability.
In contrast to lck–C3 mice, CD25+ cells from CD2–C3 mice
did not show increased levels of apoptosis (Figure 3c).
The differences between these two strains of transgenic
mice are striking: CD25+ thymocytes from CD2–C3 mice
showed a differentiation block but had no problems with
cell survival, whereas CD25+ thymocytes from lck–C3
mice were apoptotic, with the few surviving cells undergo-
ing normal differentiation. Thus, insights gained into Rho
function in CD25+ thymocytes are very different depend-
ing on whether lck–C3 transgenic mice or CD2–C3 trans-
genic mice are studied. It should be emphasised that four
independent lines of lck–C3 transgenic mice have been
generated with different copy numbers and all showed the
same phenotype — survival defects but apparently normal
thymocyte differentiation. Similarly, blocks to thymocyte
differentiation but no survival defects were seen in three
lines of CD2–C3 mice. 
Expression of the C3 transferase transcript in CD2–C3
mice could be detected on day 12 of embryogenesis,
whereas in lck–C3 mice it was detectable on day 11.
Studies in adult mice confirmed expression of C3 trans-
ferase in CD44+CD25– cells from lck–C3 mice; the
CD2-driven C3 transgene was expressed later, when
CD25+ cells appeared (see Supplementary material pub-
lished with this paper on the internet). Inhibition of Rho
before the CD25+ stage, as in the lck–C3 mice, resulted in
increased levels of cell death, but inhibition directly in
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Figure 1
The stages of thymocyte development and the
kinetics of lck and CD2 expression. Early T-cell
progenitors are CD4–CD8– (double-negative;
DN) and go through the CD44+CD25–,
CD44+CD25+, CD44–CD25+ and
CD44–CD25– stages in order [15,16]. Cells
that successfully rearrange their T-cell receptor
β-chain loci express a functional pre-T-cell
receptor (pre-TCR), downregulate CD25
expression, proliferate rapidly and differentiate
into CD4+CD8+ double-positive (DP) cells
[12,17]. CD4+CD8+ DP cells undergo TCR
α-chain rearrangements and, upon expression
of a functional TCRαβ, differentiate into mature
CD4+ or CD8+ single-positive (SP) cells [18].
The lck proximal promoter is active from the
CD44+CD25– stage until cells exit the thymus
into the periphery; CD2 expression begins in
the CD44+CD25+ population, as cells start to
rearrange their TCR β-chain loci. 
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CD25+ cells, as in the CD2–C3 mice, did not. The
increased levels of cell death in CD25+ cells from lck–C3
transgenic mice were thus not a direct consequence of loss
of Rho signalling in these thymocytes. Rather, the signals
that regulate survival of CD25+ cells must be generated by
Rho-dependent mechanisms in earlier progenitors. Once
these signals are induced, there seems to be no further
requirement for Rho function for survival of CD25+ cells.
Although the CD25+ pre-T cells in lck–C3 mice showed
increased apoptosis, the few that survived (<1% of normal)
could differentiate into CD4+CD8+ DP and CD4+ or
CD8+ SP cells. CD25+ cells from CD2–C3 mice did not
undergo apoptosis but were unable to differentiate. This
difference in differentiation potential is surprising, partic-
ularly as Rho function was completely inactivated in the
surviving thymocytes in the lck–C3 mice [4]. Possibly, pre-
T cells in lck–C3 mice have been selected for the ability to
compensate for apoptosis due to loss of Rho function. The
compensating signals that allow them to survive the loss of
Rho function could also allow them to differentiate
without Rho function. Only the direct inactivation of Rho
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(c) (d)NLC CD2–C3 transgenic CD2–C3 transgenicNLC
Phenotype of the CD2–C3 transgenic mice. (a) Thymi isolated from
4-week-old wild-type, CD2–C3, and lck–C3 transgenic mice.
(b) Thymocyte cell numbers from 4-week-old CD2–C3 transgenic and
non-transgenic littermate control (NLC) mice. Horizontal bars in (b)
represent the mean of cell numbers (n = 8). (c) Analysis of the thymic
subsets in CD2–C3 transgenic mice by flow cytometry. Thymocytes
from CD2–C3 and NLC mice were stained with phycoerythrin (PE)-
conjugated anti-CD4 and fluorescein isothiocyanate (FITC)-conjugated
anti-CD8 antibodies. (d) Analysis of the CD4–CD8– DN population
from NLC and CD2–C3 mice. ‘Lineage-negative’ thymocytes (from
which all CD4+CD8+ DP and CD4+ or CD8+ SP thymocytes as well as
all cells of non-T-cell lineage had been excluded using a panel of
biotinylated antibodies (against the markers CD4, CD8, CD3, B220,
Mac-1, NK, γδ, and Gr1, and revealed with streptavidin) were co-stained
with PE–anti-CD44 and FITC–anti-CD25 antibodies. (e) Levels of
expression of CD25 on lineage-negative thymocytes from NLC and
CD2–C3 mice were determined by antibody staining with PE–anti-
CD25. (f) Expression of rearranged TCRβ chain in CD25+ thymocytes.
Thymocytes from NLC and CD2–C3 mice were stained with PE–anti-
CD25 before saponin permeabilisation and staining with an antibody to
a common β-chain epitope. The histograms show levels of intracellular β
chain (dark blue) and surface β chain (grey) on both small (E) and large
(L) CD25+ thymocytes. (g) Expression of the HY-TCR on CD4–CD8–
DN thymocytes isolated from female HY-TCR littermate controls and
female CD2–C3/HY-TCR double-transgenic mice. Thymocytes were
stained with PE–anti-CD4, FITC–anti-CD8, and biotinylated anti-HY-
TCR antibodies, revealed with streptavidin, and the DN cells analysed
for expression of HY-TCR. (h) Analysis of the CD4 and CD8
populations in female HY-TCR and CD2–C3/HY-TCR mice.
Thymocytes were stained with PE–anti-CD4, FITC–anti-CD8, and
biotinylated anti-HY-TCR antibodies. The distribution of CD4+ and
CD8+ cells in the HY-TCR-expressing population is shown.
in pre-T cells in CD2–C3 mice reveals the essential role of
Rho for pre-T-cell differentiation.
Supplementary material
Additional methodological details and a figure showing kinetics of
transgene expression are published with this paper on the internet.
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Comparison of the CD2–C3 and lck–C3 transgenic mice.
(a) Thymocytes from lck–C3, CD2–C3 mice and nontransgenic
littermate controls (NLC) were stained with PE–anti-CD4 and
FITC–anti-CD8 antibodies. (b) Analysis of the CD4–CD8– DN
population from NLC, CD2–C3 and lck–C3 mice. Lineage-negative
thymocytes (as in Figure 2) were co-stained with PE–anti-CD44 and
FITC–anti-CD25 antibodies. (c) Thymocytes isolated from 4-week-old
mice were stained with a FITC–anti-CD25 antibody and 7AAD. The
percentage of CD25+ thymocytes of NLC, CD2–C3 and lck–C3 mice
that are 7AAD-positive are shown (n = 5).
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Supplementary materials and methods
Transgenic mice
A purified 11.2 kb KpnI–NotI fragment (2 ng/ml) containing the
CD2–C3 transgene was injected into the pronuclei of day-1 F1 mouse
zygotes (C57/BL6/J × CBA/J). Embryos were transferred into pseudo-
pregnant F1 foster mice which gave birth to litters of 5–10 mice
20 days later. Stable lines were generated by backcrossing transgene-
carrying founder mice with C57/BL6/J mice. Transgenic mice express-
ing the TCR that reacts with the male-specific HY antigen were kindly
provided by H. von Boehmer [S1].
PCR
Transgene-carrying mice were identified by PCR with transgene-spe-
cific primers: VAh2 (5′-GTCCCAACCCAGCTTTCCCTG-3′) and
C3NT (5′-CTGATTTGCTTAGTCCATAC-3′) or VAh4 (5′-GGGGA-
CAATGAGTTTTCTGCTG-3′) and C3CT (5′-GGGCACAGCTAT-
CAATCC-3′). Genomic DNA was purified from mouse ear punches
and used as template for 30 cycles of PCR (57°C annealing, 72°C
elongation, 95°C denaturation).
Reverse-transcriptase PCR (RT–PCR) from fetal thymi
Fetal thymic lobes (embryonic day 13–15) and total embryos (embry-
onic day 10–12) were dissolved in 500 µl RNazol (Cinna Scientific).
Total RNA was extracted according to the manufacturer’s instructions
and subjected to DNase treatment. The reverse transcriptase (RT)
reaction was performed using random hexamer primers, and the cDNA
obtained was used as template for PCR reactions employing primers
specific for HPRT (5′-CACAGGACTAGAACACCTGC-3′ and 5′ -
GCTGGTGAAAAGGACCTCT-3′), p56lck (5′-GCCCATCCGGAATG-
GCTCTG-3′ and 5′-CGCCACGAAGTTGAAGGG-3′) and C3
transferase (5′-GAGGGAACCCAGTCAGTCAGGAGC-3′ and 5′-CT-
GATTTGCTTAGTCCATAC-3′). PCR reactions were performed in
20 mM ammonium sulphate, 75 mM Tris–HCl pH 9.0, 0.01% Tween
20, 1.2 mM MgCI2, 200 mM dNTP, 0.5 U Taq DNA polymerase, and
1 mM of each primer. DNA was amplified for 35 cycles at an annealing
temperature of 57ºC. PCR products were separated in 2% agarose
gels and stained with ethidium bromide.
Cell preparation
Thymi were obtained by dissection from 4–6-week-old mice. Tissue
was disaggregated with fine forceps and forced through a fine mesh
filter to obtain a single-cell suspension. 
Flow cytometric analysis
Antibodies (Pharmingen) were obtained conjugated to either fluores-
cein isothiocyanate (FITC), phycoerythrin (PE) or biotin. Biotinylated
antibodies were revealed using streptavidin–tricolor (Caltag). Thymo-
cytes were stained for surface expression of the following markers
using the antibodies given in brackets: CD8 (53–5.8), CD4 (RM4-5),
CD25 (IL2Rαchain, 3C7), CD3ε (145-2C11), αβTCR (β-chain, H57-
597), B220 (CD45R, RA3-6B2), CD44 (Pgp-1, IM7), CD2 (LFA-2,
RM2-5), Mac-1 (CD11b, M1/70), Gr-1 (Ly-6G,RB6-8C5) and HY-TCR
(T3.70).  Cells were stained with saturating concentrations of antibody
at 4°C for 20 min at 2 × 106 cells per sample in a 96-well V-bottom-
shaped microtitre plate in 100 µl PBS containing 1% bovine serum
albumin. Cells were washed with this buffer between incubations and
before analysis on a Calibur fluorescence-activated cell sorter (FACS;
Becton Dickinson). Events were collected and stored ungated in list
mode using CellQuest software. Live cells were gated according to
their forward-scatter (FSC) and side-scatter (SSC) profiles and data
were analysed using CellQuest software.
Apoptosis assay
Thymocytes were stained with a FITC-labelled  monoclonal antibody
against CD25 in RPMI medium supplemented with 10% FCS. After
washing, cells were incubated with 7AAD (Calbiochem) for 20 min at
4°C in the dark. Cells were analysed by flow cytometry, with apoptotic
cells being identified by 7AAD staining as described [S2].
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Figure S1
Temporal expression of C3 transferase as
analysed by RT–PCR. RNA was prepared
from total embryos (embryonic day 10–12)
and thymic lobes (embryonic day 13–15) and
was used as a template for cDNA synthesis.
The presence of the C3 and hypoxanthine
phosphoribosyltransferase (HPRT; control)
transcripts was determined by PCR.
(a) RT–PCR analysis of C3 transferase
expression in fetal thymocytes isolated from
lck–C3 and CD2–C3 transgenic mice.
(b) RT–PCR analysis of C3 transferase
expression in sorted CD44+CD25–,
CD44+CD25+ and CD25+CD44– thymocytes
from lck–C3 and CD2–C3 mice.
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